James M Wilson

List of Publications by Year in Descending Order

574 papers	52,873 citations	123 h-index	207 g-index
640 ext. papers	57,429 ext. citations	9.3 avg, IF	7.34 L-index

#	Paper	IF	Citations
574	Prednisolone reduces the interferon response to AAV in cynomolgus macaques and may increase liver gene expression.. *Molecular Therapy - Methods and Clinical Development*, **2022**, 24, 292-305	6.4	0
573	Efficacy and Safety of a Krabbe Disease Gene Therapy.. *Human Gene Therapy*, **2022**,	4.8	2
572	CRISPR/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice. *Journal of Clinical Investigation*, **2021**, 131,	15.9	9
571	Scalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic Device. *Nano Letters*, **2021**, 21, 5671-5680	11.5	24
570	Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9. *Molecular Therapy*, **2021**, 29, 2019-2029	11.7	14
569	Intranasal gene therapy to prevent infection by SARS-CoV-2 variants. *PLoS Pathogens*, **2021**, 17, e1009546	7.46	10
568	Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver. *Biomaterials Science*, **2021**, 9, 1449-1463	7.4	16
567	Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mice and non-human primates **2021**,		4
566	Increasing the Specificity of AAV-Based Gene Editing through Self-Targeting and Short-Promoter Strategies. *Molecular Therapy*, **2021**, 29, 1047-1056	11.7	3
565	Muscle-directed AAV gene therapy rescues the maple syrup urine disease phenotype in a mouse model. *Molecular Genetics and Metabolism*, **2021**, 134, 139-146	3.7	2
564	Developing a second-generation clinical candidate AAV vector for gene therapy of familial hypercholesterolemia. *Molecular Therapy - Methods and Clinical Development*, **2021**, 22, 1-10	6.4	1
563	Context-Specific Function of the Engineered Peptide Domain of PHP.B. *Journal of Virology*, **2021**, 95, e0116421	6.6	2
562	An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. *Cell Host and Microbe*, **2021**, 29, 1437-1453.e8	23.4	20
561	Sensitive Determination of Infectious Titer of Recombinant Adeno-Associated Viruses (rAAVs) Using TCID End-Point Dilution and Quantitative Polymerase Chain Reaction (qPCR). *Cold Spring Harbor Protocols*, **2020**, 2020, 095653	1.2	2
560	ITR-Seq, a next-generation sequencing assay, identifies genome-wide DNA editing sites in vivo following adeno-associated viral vector-mediated genome editing. *BMC Genomics*, **2020**, 21, 239	4.5	14
559	Isolating Human Monoclonal Antibodies Against Adeno-Associated Virus From Donors With Pre-existing Immunity. *Frontiers in Immunology*, **2020**, 11, 1135	8.4	2
558	Adenovirus-Antibody Complexes Contributed to Lethal Systemic Inflammation in a Gene Therapy Trial. *Molecular Therapy*, **2020**, 28, 784-793	11.7	14

557	A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency. *Science Advances*, **2020**, 6, eaax5701	14.3	21
556	A Single Injection of an Optimized Adeno-Associated Viral Vector into Cerebrospinal Fluid Corrects Neurological Disease in a Murine Model of GM1 Gangliosidosis. *Human Gene Therapy*, **2020**, 31, 1169-1177	4.8	8
555	Translational Feasibility of Lumbar Puncture for Intrathecal AAV Administration. *Molecular Therapy - Methods and Clinical Development*, **2020**, 17, 969-974	6.4	8
554	MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates. *Science Translational Medicine*, **2020**, 12,	17.5	34
553	Moving Forward after Two Deaths in a Gene Therapy Trial of Myotubular Myopathy. *Genetic Engineering and Biotechnology News*, **2020**, 40, 14, 16	0.6	0
552	Adeno-Associated Virus-Induced Dorsal Root Ganglion Pathology. *Human Gene Therapy*, **2020**, 31, 808-818	4.8	44
551	Adeno-associated virus serotype 1-based gene therapy for FTD caused by GRN mutations. *Annals of Clinical and Translational Neurology*, **2020**, 7, 1843-1853	5.3	7
550	Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge. *Frontiers in Immunology*, **2020**, 11, 626464	8.4	2
549	A Birds-Eye View: An Interview with Nick Leschly. *Human Gene Therapy Clinical Development*, **2019**, 30, 5-6	3.2	
548	Breakthrough to Bedside: Bringing Gene Therapy to Neuromuscular Diseases. *Human Gene Therapy Clinical Development*, **2019**, 30, 93-96	3.2	0
547	A Gene Therapy Approach to Improve Copper Metabolism and Prevent Liver Damage in a Mouse Model of Wilson Disease. *Human Gene Therapy Clinical Development*, **2019**, 30, 29-39	3.2	7
546	Safe and Sustained Expression of Human Iduronidase After Intrathecal Administration of Adeno-Associated Virus Serotype 9 in Infant Rhesus Monkeys. *Human Gene Therapy*, **2019**, 30, 957-966	4.8	34
545	The GPI-Linked Protein LY6A Drives AAV-PHP.B Transport across the Blood-Brain Barrier. *Molecular Therapy*, **2019**, 27, 912-921	11.7	86
544	CRISPR/Cas9-mediated in vivo gene targeting corrects hemostasis in newborn and adult factor IX-knockout mice. *Blood*, **2019**, 133, 2745-2752	2.2	32
543	Cycling at the Frontiers of Gene Therapy. *Human Gene Therapy Clinical Development*, **2019**, 30, 47-49	3.2	1
542	Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening. *Journal of Controlled Release*, **2019**, 316, 404-417	11.7	42
541	TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy. *Cellular Immunology*, **2019**, 346, 103997	4.4	14
540	Susceptibility to SIV Infection After Adenoviral Vaccination in a Low Dose Rhesus Macaque Challenge Model. *Pathogens and Immunity*, **2019**, 4, 1-20	4.9	2

539	Adeno-associated virus-mediated expression of human butyrylcholinesterase to treat organophosphate poisoning. *PLoS ONE*, **2019**, 14, e0225188	3.7	4
538	Interview with Jean Bennett, MD, PhD. *Human Gene Therapy Clinical Development*, **2018**, 29, 7-9	3.2	3
537	Assessment of Humoral, Innate, and T-Cell Immune Responses to Adeno-Associated Virus Vectors. *Human Gene Therapy Methods*, **2018**, 29, 86-95	4.9	31
536	Assessment of humoral, innate, and T-cell immune responses to adeno-associated virus vectors. *Human Gene Therapy Methods*, **2018**,	4.9	2
535	AAV8 Gene Therapy Rescues the Newborn Phenotype of a Mouse Model of Crigler-Najjar. *Human Gene Therapy*, **2018**, 29, 763-770	4.8	15
534	The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. *Molecular Therapy*, **2018**, 26, 664-668	11.7	199
533	Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. *Human Gene Therapy*, **2018**, 29, 285-298	4.8	321
532	AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration. *Molecular Therapy*, **2018**, 26, 542-549	11.7	26
531	Lancet Commission: Stem cells and regenerative medicine. *Lancet, The*, **2018**, 391, 883-910	40	124
530	Evaluation of Intrathecal Routes of Administration for Adeno-Associated Viral Vectors in Large Animals. *Human Gene Therapy*, **2018**, 29, 15-24	4.8	57
529	Standardized Method for Intra-Cisterna Magna Delivery Under Fluoroscopic Guidance in Nonhuman Primates. *Human Gene Therapy Methods*, **2018**, 29, 212-219	4.9	11
528	Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Human Alpha-L-Iduronidase in Rhesus Macaques. *Molecular Therapy - Methods and Clinical Development*, **2018**, 10, 79-88	6.4	49
527	Meganuclease targeting of PCSK9 in macaque liver leads to stable reduction in serum cholesterol. *Nature Biotechnology*, **2018**, 36, 717-725	44.5	57
526	Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Iduronate-2-Sulfatase in Rhesus Macaques. *Molecular Therapy - Methods and Clinical Development*, **2018**, 10, 68-78	6.4	36
525	Mapping an Adeno-associated Virus 9-Specific Neutralizing Epitope To Develop Next-Generation Gene Delivery Vectors. *Journal of Virology*, **2018**, 92,	6.6	19
524	Determining the Minimally Effective Dose of a Clinical Candidate AAV Vector in a Mouse Model of Crigler-Najjar Syndrome. *Molecular Therapy - Methods and Clinical Development*, **2018**, 10, 237-244	6.4	5
523	Optimized Adeno-Associated Viral-Mediated Human Factor VIII Gene Therapy in Cynomolgus Macaques. *Human Gene Therapy*, **2018**,	4.8	9
522	Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. *Journal of Virology*, **2018**, 92,	6.6	19

521	Tachi Yamada: An Academic, Drug Developer and Humanist. *Human Gene Therapy Clinical Development*, **2018**, 29, 176-178	3.2	
520	AAV8 Gene Therapy for Crigler-Najjar Syndrome in Macaques Elicited Transgene T Cell Responses That Are Resident to the Liver. *Molecular Therapy - Methods and Clinical Development*, **2018**, 11, 191-201	6.4	7
519	University Flunk-Out to Genomics Pioneer: An Interview with George Church, PhD. *Human Gene Therapy Clinical Development*, **2018**, 29, 118-120	3.2	
518	Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin. *Science*, **2018**, 362, 598-602	33.3	106
517	Deamidation of Amino Acids on the Surface of Adeno-Associated Virus Capsids Leads to Charge Heterogeneity and Altered Vector Function. *Molecular Therapy*, **2018**, 26, 2848-2862	11.7	34
516	Adeno-associated viral gene therapy corrects a mouse model of argininosuccinic aciduria. *Molecular Genetics and Metabolism*, **2018**, 125, 241-250	3.7	9
515	Accurate and Rapid Sequence Analysis of Adeno-Associated Virus Plasmids by Illumina Next-Generation Sequencing. *Human Gene Therapy Methods*, **2018**, 29, 201-211	4.9	5
514	Intrathecal Viral Vector Delivery of Trastuzumab Prevents or Inhibits Tumor Growth of Human HER2-Positive Xenografts in Mice. *Cancer Research*, **2018**, 78, 6171-6182	10.1	11
513	Preparation of Nonhuman Primate Eyes for Histological Evaluation After Retinal Gene Transfer. *Human Gene Therapy Methods*, **2018**, 29, 115-123	4.9	
512	Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice. *Human Gene Therapy*, **2017**, 28, 392-402	4.8	18
511	Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for α1-antitrypsin deficiency. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 1655-1659	11.5	34
510	AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice. *Molecular Genetics and Metabolism*, **2017**, 120, 299-305	3.7	24
509	Jurassic Park, Gene Therapy, and Neuroscience: An Interview with Feng Zhang, PhD. *Human Gene Therapy Clinical Development*, **2017**, 28, 4-6	3.2	
508	5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency. *Molecular Therapy*, **2017**, 25, 1387-1394	11.7	60
507	Alternative Start Sites Downstream of Non-Sense Mutations Drive Antigen Presentation and Tolerance Induction to C-Terminal Epitopes. *Journal of Immunology*, **2017**, 198, 4581-4587	5.3	0
506	The Past, Present, and Future of Gene Therapy from Nobel Laureate David Baltimore. *Human Gene Therapy Clinical Development*, **2017**, 28, 65-67	3.2	0
505	Non-Clinical Study Examining AAV8.TBG.hLDLR Vector-Associated Toxicity in Chow-Fed Wild-Type and LDLR Rhesus Macaques. *Human Gene Therapy Clinical Development*, **2017**, 28, 39-50	3.2	27
504	Regulatory and Exhausted T Cell Responses to AAV Capsid. *Human Gene Therapy*, **2017**, 28, 338-349	4.8	33

503	Nonclinical Pharmacology/Toxicology Study of AAV8.TBG.mLDLR and AAV8.TBG.hLDLR in a Mouse Model of Homozygous Familial Hypercholesterolemia. *Human Gene Therapy Clinical Development*, **2017**, 28, 28-38	3.2	20
502	Wnt10b and Dkk-1 gene therapy differentially influenced trabecular bone architecture, soft tissue integrity, and osteophytosis in a skeletally mature rat model of osteoarthritis. *Connective Tissue Research*, **2017**, 58, 542-552	3.3	8
501	Challenges in the gene therapy commercial ecosystem. *Nature Biotechnology*, **2017**, 35, 813-815	44.5	6
500	The Story of RNA Interference as a New Therapeutic Paradigm from Nobel Laureate Craig Mello. *Human Gene Therapy Clinical Development*, **2017**, 28, 121-125	3.2	
499	Abnormal polyamine metabolism is unique to the neuropathic forms of MPS: potential for biomarker development and insight into pathogenesis. *Human Molecular Genetics*, **2017**, 26, 3837-3849	5.6	4
498	Carl June Speaks of His Pioneering Efforts That Led to the First Food and Drug Administration-Approved Gene Therapy Product. *Human Gene Therapy Clinical Development*, **2017**, 28, 175-177	3.2	1
497	The Gene Therapy Resource Program: A Decade of Dedication to Translational Research by the National Heart, Lung, and Blood Institute. *Human Gene Therapy Clinical Development*, **2017**, 28, 178-186	3.2	0
496	Delivery of an Adeno-Associated Virus Vector into Cerebrospinal Fluid Attenuates Central Nervous System Disease in Mucopolysaccharidosis Type II Mice. *Human Gene Therapy*, **2016**, 27, 906-915	4.8	28
495	Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model. *Molecular Genetics and Metabolism*, **2016**, 119, 124-30	3.7	23
494	Recollections from a Pioneer Who Provided the Foundation for the Success of Gene Therapy in Treating Severe Combined Immune Deficiencies. *Human Gene Therapy Clinical Development*, **2016**, 27, 53-6	3.2	1
493	Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques. *Vaccine*, **2016**, 34, 6323-6329	4.1	23
492	AAV Natural Infection Induces Broad Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in Chimpanzees. *Human Gene Therapy Clinical Development*, **2016**, 27, 79-82	3.2	38
491	Stable liver-specific expression of human IDOL in humanized mice raises plasma cholesterol. *Cardiovascular Research*, **2016**, 110, 23-9	9.9	11
490	Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII. *Molecular Therapy*, **2016**, 24, 206-216	11.7	56
489	Interview with Inder Verma, PhD. *Human Gene Therapy Clinical Development*, **2016**, 27, 5-8	3.2	1
488	Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia. *Human Gene Therapy*, **2016**, 27, 345-53	4.8	20
487	A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. *Nature Biotechnology*, **2016**, 34, 334-8	44.5	360
486	Crispr/Cas9-Mediated In Vivo Gene Targeting Corrects Haemostasis in Newborn and Adult FIX-KO Mice. *Blood*, **2016**, 128, 1174-1174	2.2	2

485	Strategies for Selection of AAV Vectors for Administration to Liver: Studies in Nonhuman Primates. *Blood*, **2016**, 128, 2316-2316	2.2	1
484	A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis. *Efficacy and Mechanism Evaluation*, **2016**, 3, 1-210	1.7	18
483	Effects of Self-Complementarity, Codon Optimization, Transgene, and Dose on Liver Transduction with AAV8. *Human Gene Therapy Methods*, **2016**, 27, 228-237	4.9	13
482	Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaques. *Molecular Therapy - Methods and Clinical Development*, **2016**, 3, 16079	6.4	8
481	Adeno-Associated Virus Serotype 9-Expressed ZMapp in Mice Confers Protection Against Systemic and Airway-Acquired Ebola Virus Infection. *Journal of Infectious Diseases*, **2016**, 214, 1975-1979	7	13
480	Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. *Lancet Respiratory Medicine,the*, **2015**, 3, 684-691	35.1	267
479	Development and rescue of human familial hypercholesterolaemia in a xenograft mouse model. *Nature Communications*, **2015**, 6, 7339	17.4	38
478	Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates. *Molecular Therapy*, **2015**, 23, 1298-1307	11.7	56
477	Preexisting Neutralizing Antibodies to Adeno-Associated Virus Capsids in Large Animals Other Than Monkeys May Confound In Vivo Gene Therapy Studies. *Human Gene Therapy Methods*, **2015**, 26, 103-5	4.9	32
476	Motor neuron transduction after intracisternal delivery of AAV9 in a cynomolgus macaque. *Human Gene Therapy Methods*, **2015**, 26, 43-4	4.9	4
475	Human immune system mice immunized with Plasmodium falciparum circumsporozoite protein induce protective human humoral immunity against malaria. *Journal of Immunological Methods*, **2015**, 427, 42-50	2.5	25
474	Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. *Molecular Therapy*, **2015**, 23, 1877-87	11.7	67
473	Humoral and cell-mediated immune response, and growth factor synthesis after direct intraarticular injection of rAAV2-IGF-I and rAAV5-IGF-I in the equine middle carpal joint. *Human Gene Therapy*, **2015**, 26, 161-71	4.8	11
472	Structure of neurotropic adeno-associated virus AAVrh.8. *Journal of Structural Biology*, **2015**, 192, 21-36	3.4	33
471	Identification of an adeno-associated virus binding epitope for AVB sepharose affinity resin. *Molecular Therapy - Methods and Clinical Development*, **2015**, 2, 15040	6.4	23
470	There and Back Again: Mitchell Finer on the Journey of Biotech from Start-Up to Success. *Human Gene Therapy Clinical Development*, **2015**, 26, 140-3	3.2	2
469	A Journey in the Development of Gene Therapy for Inherited Disorders of the Bone Marrow. *Human Gene Therapy Clinical Development*, **2015**, 26, 203-7	3.2	
468	Perspectives on best practices for gene therapy programs. *Human Gene Therapy*, **2015**, 26, 127-33	4.8	10

467	The Next Chapter. *Human Gene Therapy*, **2015**, 26, 331	4.8	1
466	Defensin 1 plays a role in acute mucosal defense against Candida albicans. *Journal of Immunology*, **2015**, 194, 1788-95	5.3	66
465	Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR. *Human Gene Therapy Methods*, **2014**, 25, 115-25	4.9	77
464	Liver-directed gene therapy corrects cardiovascular lesions in feline mucopolysaccharidosis type I. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 14894-9	11.5	35
463	Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I. *Molecular Therapy*, **2014**, 22, 2018-2027	11.7	71
462	Adeno-associated virus 9-mediated airway expression of antibody protects old and immunodeficient mice against influenza virus. *Vaccine Journal*, **2014**, 21, 1528-33		25
461	Increased mucosal CD4+ T cell activation in rhesus macaques following vaccination with an adenoviral vector. *Journal of Virology*, **2014**, 88, 8468-78	6.6	23
460	The special case of gene therapy pricing. *Nature Biotechnology*, **2014**, 32, 874-6	44.5	52
459	The structure of AAVrh32.33, a novel gene delivery vector. *Journal of Structural Biology*, **2014**, 186, 308-17	3.4	26
458	Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna. *Molecular Therapy - Methods and Clinical Development*, **2014**, 1, 14051	6.4	58
457	Intramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression. *PLoS ONE*, **2014**, 9, e112268	3.7	33
456	AAV vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia. *Circulation Research*, **2014**, 115, 591-9	15.7	29
455	P204 Immune Responses To Single And Repeated Administration Of Pgm169/gl67a: The Uk Cf Gene Therapy Consortium Clinical Trials. *Thorax*, **2014**, 69, A166-A166	7.3	
454	AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells. *Molecular Therapy*, **2014**, 22, 28-41	11.7	38
453	In vivo evaluation of adeno-associated virus gene transfer in airways of mice with acute or chronic respiratory infection. *Human Gene Therapy*, **2014**, 25, 966-76	4.8	6
452	Genetic diseases, immunology, viruses, and gene therapy. *Human Gene Therapy*, **2014**, 25, 257-61	4.8	7
451	Formation of newly synthesized adeno-associated virus capsids in the cell nucleus. *Human Gene Therapy Methods*, **2014**, 25, 179-80	4.9	
450	AAV8 capsid variable regions at the two-fold symmetry axis contribute to high liver transduction by mediating nuclear entry and capsid uncoating. *Virology*, **2014**, 454-455, 227-36	3.6	11

449	An AAV vector-mediated gene delivery approach facilitates reconstitution of functional human CD8+ T cells in mice. *PLoS ONE*, **2014**, 9, e88205	3.7	31
448	Lessons learned from the clinical development and market authorization of Glybera. *Human Gene Therapy Clinical Development*, **2013**, 24, 55-64	3.2	128
447	Enhancing the utility of adeno-associated virus gene transfer through inducible tissue-specific expression. *Human Gene Therapy Methods*, **2013**, 24, 270-8	4.9	22
446	Self-reactive CFTR T cells in humans: implications for gene therapy. *Human Gene Therapy Clinical Development*, **2013**, 24, 108-15	3.2	7
445	HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 16538-43	11.5	208
444	Bulls, bubbles, and biotech. *Human Gene Therapy*, **2013**, 24, 715-6	4.8	5
443	Gene therapy for mucopolysaccharidosis type VI is effective in cats without pre-existing immunity to AAV8. *Human Gene Therapy*, **2013**, 24, 163-9	4.8	32
442	Single nucleotide polymorphisms in cholesteryl ester transfer protein gene and recurrent coronary heart disease or mortality in patients with established atherosclerosis. *American Journal of Cardiology*, **2013**, 112, 1287-92	3	3
441	Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. *Molecular Therapy*, **2013**, 21, 266-8	11.7	11
440	Monocular and binocular low-contrast visual acuity and optical coherence tomography in pediatric multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2013**, 3, 326-334	4	26
439	Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza. *Science Translational Medicine*, **2013**, 5, 187ra72	17.5	77
438	The role of apoptosis in immune hyporesponsiveness following AAV8 liver gene transfer. *Molecular Therapy*, **2013**, 21, 2227-35	11.7	14
437	Multiple recombinant adeno-associated viral vector serotypes display persistent in vivo gene expression in vector-transduced rat stifle joints. *Human Gene Therapy Methods*, **2013**, 24, 185-94	4.9	6
436	Flushing out antibodies to make AAV gene therapy available to more patients. *Molecular Therapy*, **2013**, 21, 269-71	11.7	4
435	Advancing translational research through the NHLBI Gene Therapy Resource Program (GTRP). *Human Gene Therapy Clinical Development*, **2013**, 24, 5-10	3.2	4
434	Humoral Immune Response to AAV. *Frontiers in Immunology*, **2013**, 4, 341	8.4	140
433	Vectored expression of the broadly neutralizing antibody FI6 in mouse airway provides partial protection against a new avian influenza A virus, H7N9. *Vaccine Journal*, **2013**, 20, 1836-7		21
432	Mapping the structural determinants responsible for enhanced T cell activation to the immunogenic adeno-associated virus capsid from isolate rhesus 32.33. *Journal of Virology*, **2013**, 87, 9473-85	6.6	17

431	Recombinant adeno-associated virus integration sites in murine liver after ornithine transcarbamylase gene correction. *Human Gene Therapy*, **2013**, 24, 520-5	4.8	31
430	Biodistribution of AAV8 vectors expressing human low-density lipoprotein receptor in a mouse model of homozygous familial hypercholesterolemia. *Human Gene Therapy Clinical Development*, **2013**, 24, 154-60	3.2	28
429	Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia. *Human Gene Therapy*, **2013**, 24, 19-26	4.8	56
428	Vector sequences are not detected in tumor tissue from research subjects with ornithine transcarbamylase deficiency who previously received adenovirus gene transfer. *Human Gene Therapy*, **2013**, 24, 814-9	4.8	2
427	Vector Sequences Are Not Detected In Tumor Tissue From Research Subjects With Ornithine Transcarbamylase Deficiency Who Previously Received Adenovirus Gene Transfer. *Human Gene Therapy*, **2013**, 130827105058001	4.8	
426	In memory of Sonia Skarlatos, PhD (1953-2013). *Human Gene Therapy*, **2013**, 24, 895	4.8	
425	AAV9 targets cone photoreceptors in the nonhuman primate retina. *PLoS ONE*, **2013**, 8, e53463	3.7	67
424	CpG-depleted adeno-associated virus vectors evade immune detection. *Journal of Clinical Investigation*, **2013**, 123, 2994-3001	15.9	123
423	Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. *Journal of Clinical Investigation*, **2013**, 123, 5310-8	15.9	112
422	Chromosome 9p21 single nucleotide polymorphisms are not associated with recurrent myocardial infarction in patients with established coronary artery disease. *Circulation Journal*, **2012**, 76, 950-6	2.9	23
421	Hepatocellular carcinoma in a research subject with ornithine transcarbamylase deficiency. *Molecular Genetics and Metabolism*, **2012**, 105, 263-5	3.7	27
420	Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome. *Molecular Genetics and Metabolism*, **2012**, 105, 203-11	3.7	40
419	Pseudotyped adeno-associated viral vector tropism and transduction efficiencies in murine wound healing. *Wound Repair and Regeneration*, **2012**, 20, 592-600	3.6	13
418	Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping. *Molecular Therapy*, **2012**, 20, 580-9	11.7	64
417	It's time for gene therapy to get disruptive!. *Human Gene Therapy*, **2012**, 23, 1-3	4.8	9
416	Adenoviruses in fecal samples from asymptomatic rhesus macaques, United States. *Emerging Infectious Diseases*, **2012**, 18, 1081-8	10.2	23
415	RPGR-associated retinal degeneration in human X-linked RP and a murine model **2012**, 53, 5594-608		49
414	Identification of the galactose binding domain of the adeno-associated virus serotype 9 capsid. *Journal of Virology*, **2012**, 86, 7326-33	6.6	79

413	Analysis of particle content of recombinant adeno-associated virus serotype 8 vectors by ion-exchange chromatography. *Human Gene Therapy Methods*, **2012**, 23, 56-64	4.9	51
412	A New Open Access Partner. *Human Gene Therapy*, **2012**, 23, 437-437	4.8	
411	Hepatic gene transfer in neonatal mice by adeno-associated virus serotype 8 vector. *Human Gene Therapy*, **2012**, 23, 533-9	4.8	68
410	Sustained correction of OTC deficiency in spf(ash) mice using optimized self-complementary AAV2/8 vectors. *Gene Therapy*, **2012**, 19, 404-10	4	32
409	Influence of serotype, cell type, tissue composition, and time after inoculation on gene expression in recombinant adeno-associated viral vector-transduced equine joint tissues. *American Journal of Veterinary Research*, **2012**, 73, 1178-85	1.1	13
408	Pseudotyped AAV vector-mediated gene transfer in a human fetal trachea xenograft model: implications for in utero gene therapy for cystic fibrosis. *PLoS ONE*, **2012**, 7, e43633	3.7	15
407	Inflammation promotes the loss of adeno-associated virus-mediated transgene expression in mouse liver. *Gastroenterology*, **2011**, 141, 348-57, 357.e1-3	13.3	27
406	Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9. *Gene Therapy*, **2011**, 18, 517-27	4	73
405	Inverse zonation of hepatocyte transduction with AAV vectors between mice and non-human primates. *Molecular Genetics and Metabolism*, **2011**, 104, 395-403	3.7	41
404	Adenoviruses in lymphocytes of the human gastro-intestinal tract. *PLoS ONE*, **2011**, 6, e24859	3.7	48
403	Muscle-directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors. *Journal of Thrombosis and Haemostasis*, **2011**, 9, 2009-19	15.4	18
402	Usefulness of single nucleotide polymorphism in chromosome 4q25 to predict in-hospital and long-term development of atrial fibrillation and survival in patients undergoing coronary artery bypass grafting. *American Journal of Cardiology*, **2011**, 107, 1504-9	3	32
401	Creation of a panel of vectors based on ape adenovirus isolates. *Journal of Gene Medicine*, **2011**, 13, 17-25	3.5	26
400	AAV8-mediated hepatic gene transfer in infant rhesus monkeys (Macaca mulatta). *Molecular Therapy*, **2011**, 19, 2012-20	11.7	62
399	Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. *Human Gene Therapy*, **2011**, 22, 1239-47	4.8	253
398	Cardiac gene transfer of short hairpin RNA directed against phospholamban effectively knocks down gene expression but causes cellular toxicity in canines. *Human Gene Therapy*, **2011**, 22, 969-77	4.8	35
397	Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. *Human Gene Therapy*, **2011**, 22, 1389-401	4.8	129
396	The Birth of Human Gene Therapy Methods. *Human Gene Therapy*, **2011**, 22, 1031-1032	4.8	0

395	Human CRB1-associated retinal degeneration: comparison with the rd8 Crb1-mutant mouse model **2011**, 52, 6898-910		87
394	Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. *Science Translational Medicine*, **2011**, 3, 88ra54	17.5	150
393	Adeno-associated virus antibody profiles in newborns, children, and adolescents. *Vaccine Journal*, **2011**, 18, 1586-8		197
392	New Candidate Vaccines against Blood-Stage Plasmodium falciparum Malaria: Prime-Boost Immunization Regimens Incorporating Human and Simian Adenoviral Vectors and Poxviral Vectors Expressing an Optimized Antigen Based on Merozoite Surface Protein 1. *Infection and Immunity*, **2011**, 79, 2132-2132	3.7	78
391	Construction of gene transfer vectors based on simian adenovirus 7. *Journal of General Virology*, **2011**, 92, 1749-1753	4.9	10
390	Evaluation of adeno-associated viral vectors for liver-directed gene transfer in dogs. *Human Gene Therapy*, **2011**, 22, 985-97	4.8	33
389	The History and Promise of Gene Therapy. *Genetic Engineering and Biotechnology News*, **2011**, 31, 62-65	0.6	2
388	Identification and functional characterization in vivo of a novel splice variant of LDLR in rhesus macaques. *Physiological Genomics*, **2011**, 43, 911-6	3.6	3
387	The complex and evolving story of T cell activation to AAV vector-encoded transgene products. *Molecular Therapy*, **2011**, 19, 16-27	11.7	99
386	The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. *Journal of Clinical Investigation*, **2011**, 121, 2427-35	15.9	122
385	Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis. *PLoS ONE*, **2010**, 5, e13424	3.7	52
384	New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1. *Infection and Immunity*, **2010**, 78, 4601-12	3.7	44
383	Molecular analysis of vector genome structures after liver transduction by conventional and self-complementary adeno-associated viral serotype vectors in murine and nonhuman primate models. *Human Gene Therapy*, **2010**, 21, 750-61	4.8	23
382	Activation of transgene-specific T cells following lentivirus-mediated gene delivery to mouse lung. *Molecular Therapy*, **2010**, 18, 143-50	11.7	28
381	Fetoprotein gene delivery to the nasal epithelium of nonhuman primates by human parainfluenza viral vectors. *Human Gene Therapy*, **2010**, 21, 1657-64	4.8	6
380	Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing. *Human Gene Therapy*, **2010**, 21, 1251-7	4.8	88
379	AAV vectors avoid inflammatory signals necessary to render transduced hepatocyte targets for destructive T cells. *Molecular Therapy*, **2010**, 18, 977-82	11.7	39
378	Systematic evaluation of AAV vectors for liver directed gene transfer in murine models. *Molecular Therapy*, **2010**, 18, 118-25	11.7	99

377	Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies. *Clinical Lipidology*, **2010**, 5, 793-809		9
376	The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques. *Molecular Therapy*, **2010**, 18, 126-34	11.7	101
375	Efficient gene transfer into the mouse lung by fetal intratracheal injection of rAAV2/6.2. *Molecular Therapy*, **2010**, 18, 2130-8	11.7	31
374	Autoimmunity, recessive diseases, and gene replacement therapy. *Molecular Therapy*, **2010**, 18, 2045-7	11.7	5
373	Dual reporter comparative indexing of rAAV pseudotyped vectors in chimpanzee airway. *Molecular Therapy*, **2010**, 18, 594-600	11.7	46
372	BALB/c mice show impaired hepatic tolerogenic response following AAV gene transfer to the liver. *Molecular Therapy*, **2010**, 18, 766-74	11.7	25
371	Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. *Human Gene Therapy*, **2010**, 21, 1259-71	4.8	231
370	Lung homing CTLs and their proliferation ability are important correlates of vaccine protection against influenza. *Vaccine*, **2010**, 28, 5669-75	4.1	19
369	Preoperative statin therapy decreases risk of postoperative renal insufficiency. *Cardiovascular Therapeutics*, **2010**, 28, 80-6	3.3	35
368	In the Beginning: Reflections on the Genesis of Molecular Therapy. *Molecular Therapy*, **2010**, 18, 9-10	11.7	
367	Host immune responses to chronic adenovirus infections in human and nonhuman primates. *Journal of Virology*, **2009**, 83, 2623-31	6.6	54
366	Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. *Journal of Infectious Diseases*, **2009**, 199, 381-90	7	502
365	Adeno-associated virus capsid structure drives CD4-dependent CD8+ T cell response to vector encoded proteins. *Journal of Immunology*, **2009**, 182, 6051-60	5.3	71
364	Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 16363-8	11.5	259
363	Functional cystic fibrosis transmembrane conductance regulator expression in cystic fibrosis airway epithelial cells by AAV6.2-mediated segmental trans-splicing. *Human Gene Therapy*, **2009**, 20, 267-81	4.8	43
362	A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque. *Journal of Virology*, **2009**, 83, 12738-50	6.6	45
361	Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses. *Human Gene Therapy*, **2009**, 20, 930-42	4.8	75
360	Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. *Molecular Therapy*, **2009**, 17, 294-301	11.7	123

359	Cationic lipid formulations alter the in vivo tropism of AAV2/9 vector in lung. *Molecular Therapy*, **2009**, 17, 2078-87	11.7	19
358	Isolation and characterization of adenoviruses persistently shed from the gastrointestinal tract of non-human primates. *PLoS Pathogens*, **2009**, 5, e1000503	7.6	109
357	Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo. *Journal of Virology*, **2009**, 83, 5567-73	6.6	50
356	Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. *Hepatology*, **2009**, 50, 612-21	11.2	163
355	Identification of the murine AAVrh32.33 capsid-specific CD8+ T cell epitopes. *Journal of Gene Medicine*, **2009**, 11, 1095-102	3.5	9
354	Tailoring the AAV vector capsid for gene therapy. *Gene Therapy*, **2009**, 16, 311-9	4	135
353	Identification of the murine firefly luciferase-specific CD8 T-cell epitopes. *Gene Therapy*, **2009**, 16, 441-7	4	43
352	Identification of the immunodominant cytotoxic T-cell epitope of human alpha-1 antitrypsin. *Gene Therapy*, **2009**, 16, 1380-2	4	3
351	Naturally occurring singleton residues in AAV capsid impact vector performance and illustrate structural constraints. *Gene Therapy*, **2009**, 16, 1416-28	4	49
350	Medicine. A history lesson for stem cells. *Science*, **2009**, 324, 727-8	33.3	84
349	Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. *Molecular Genetics and Metabolism*, **2009**, 96, 151-7	3.7	194
348	Adenovirus-adeno-associated virus hybrid for large-scale recombinant adeno-associated virus production. *Human Gene Therapy*, **2009**, 20, 922-9	4.8	38
347	When Selecting an Adeno-associated Viral Vector Serotype, Cell Monolayer Transduction Efficiency Does Not Accurately Predict Tissue Transduction Efficiency in Equine Synovial Tissues. *FASEB Journal*, **2009**, 23, 817.7	0.9	1
346	Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. *American Journal of Cardiology*, **2008**, 102, 1438-43	3	120
345	Specific AAV serotypes stably transduce primary hippocampal and cortical cultures with high efficiency and low toxicity. *Brain Research*, **2008**, 1190, 15-22	3.7	57
344	Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue virus that are present in all major serotypes. *Human Gene Therapy*, **2008**, 19, 927-36	4.8	22
343	HCO3(-) secretion by murine nasal submucosal gland serous acinar cells during Ca2+-stimulated fluid secretion. *Journal of General Physiology*, **2008**, 132, 161-83	3.4	22
342	Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. *Human Gene Therapy*, **2008**, 19, 1359-68	4.8	218

341	Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. *Journal of Virology*, **2008**, 82, 3822-33	6.6	55
340	Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 15112-7	11.5	575
339	Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. *Molecular Therapy*, **2008**, 16, 1710-8	11.7	133
338	Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines. *Molecular Therapy*, **2008**, 16, 1953-9	11.7	69
337	Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines. *Human Gene Therapy*, **2008**, 19, 663-9	4.8	44
336	Novel AAV serotypes for improved ocular gene transfer. *Journal of Gene Medicine*, **2008**, 10, 375-82	3.5	154
335	ADENOVIRUS BASED VACCINES GENERATE CYTOTOXIC T LYMPHOCYTES TO EPITOPES OF NS1 FROM DENGUE VIRUS THAT ARE PRESENT IN ALL MAJOR SEROTYPES. *Human Gene Therapy*, **2008**, 081015093227032	4.8	
334	Structure-based identification of a major neutralizing site in an adenovirus hexon. *Journal of Virology*, **2007**, 81, 1680-9	6.6	80
333	Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. *Human Gene Therapy*, **2007**, 18, 195-206	4.8	237
332	Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. *Cardiovascular Diabetology*, **2007**, 6, 15	8.7	58
331	Optical imaging of Ca2+-evoked fluid secretion by murine nasal submucosal gland serous acinar cells. *Journal of Physiology*, **2007**, 582, 1099-124	3.9	27
330	Gene transfer in human skin with different pseudotyped HIV-based vectors. *Gene Therapy*, **2007**, 14, 648-56	4	25
329	Pulmonary delivery of adenovirus vector formulated with dexamethasone-spermine facilitates homologous vector re-administration. *Gene Therapy*, **2007**, 14, 1594-604	4	20
328	Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 16-24	15.4	151
327	Rescue of chimeric adenoviral vectors to expand the serotype repertoire. *Journal of Virological Methods*, **2007**, 141, 14-21	2.6	5
326	A comparative analysis of novel fluorescent proteins as reporters for gene transfer studies. *Journal of Histochemistry and Cytochemistry*, **2007**, 55, 931-9	3.4	16
325	Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice. *Journal of Infectious Diseases*, **2007**, 196 Suppl 2, S413-20	7	42
324	Human immunodeficiency viral vector pseudotyped with the spike envelope of severe acute respiratory syndrome coronavirus transduces human airway epithelial cells and dendritic cells. *Human Gene Therapy*, **2007**, 18, 413-22	4.8	24

323	Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice. *Journal of Virology*, **2007**, 81, 11840-9	6.6	54
322	Human cone photoreceptor dependence on RPE65 isomerase. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 15123-8	11.5	122
321	The p38 mitogen-activated protein kinase signaling pathway is coupled to Toll-like receptor 5 to mediate gene regulation in response to Pseudomonas aeruginosa infection in human airway epithelial cells. *Infection and Immunity*, **2007**, 75, 5985-92	3.7	34
320	AAV as an immunogen. *Current Gene Therapy*, **2007**, 7, 325-33	4.3	59
319	A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. *Molecular Therapy*, **2007**, 15, 608-17	11.7	30
318	Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. *Molecular Therapy*, **2007**, 15, 481-91	11.7	134
317	Activation of CFTR-specific T Cells in cystic fibrosis mice following gene transfer. *Molecular Therapy*, **2007**, 15, 1694-700	11.7	17
316	Prediction of cellular immune responses against CFTR in patients with cystic fibrosis after gene therapy. *American Journal of Respiratory Cell and Molecular Biology*, **2007**, 36, 529-33	5.7	16
315	Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. *Human Gene Therapy*, **2007**, 18, 185-94	4.8	93
314	Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. *Journal of Virology*, **2007**, 81, 11372-80	6.6	185
313	Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques. *Vaccine*, **2007**, 25, 5220-31	4.1	54
312	Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. *Vaccine*, **2007**, 25, 6845-51	4.1	72
311	Detection of reporter gene expression in murine airways. *Methods in Molecular Biology*, **2007**, 411, 25-34	1.4	3
310	Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. *Virology*, **2006**, 346, 394-401	3.6	108
309	High-level transgene expression in nonhuman primate liver with novel adeno-associated virus serotypes containing self-complementary genomes. *Journal of Virology*, **2006**, 80, 6192-4	6.6	70
308	Identification of Novel Adeno-Associated Virus Serotypes for Use as Vectors **2006**, 17-24		
307	A common mechanism for cytoplasmic dynein-dependent microtubule binding shared among adeno-associated virus and adenovirus serotypes. *Journal of Virology*, **2006**, 80, 7781-5	6.6	48
306	Complete prevention of atherosclerosis in apoE-deficient mice by hepatic human apoE gene transfer with adeno-associated virus serotypes 7 and 8. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, 1852-7	9.4	48

305	Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. *Human Gene Therapy*, **2006**, 17, 500-6	4.8	45
304	Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. *Molecular Therapy*, **2006**, 13, 77-87	11.7	132
303	High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. *Molecular Therapy*, **2006**, 13, 67-76	11.7	103
302	Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. *Molecular Therapy*, **2006**, 14, 34-44	11.7	104
301	Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors. *Molecular Therapy*, **2006**, 14, 25-33	11.7	65
300	Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 12993-8	11.5	119
299	Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. *Nature Medicine*, **2006**, 12, 967-71	50.5	174
298	Chimpanzee-origin adenovirus vectors as vaccine carriers. *Gene Therapy*, **2006**, 13, 421-9	4	79
297	Efficacy of Severe Acute Respiratory Syndrome Vaccine Based on a Nonhuman Primate Adenovirus in the Presence of Immunity Against Human Adenovirus. *Human Gene Therapy*, **2006**, 060801084750002	4.8	
296	Generation of an adenoviral vaccine vector based on simian adenovirus 21. *Journal of General Virology*, **2006**, 87, 2477-2485	4.9	36
295	Long-term inducible gene expression in the eye via adeno-associated virus gene transfer in nonhuman primates. *Human Gene Therapy*, **2005**, 16, 178-86	4.8	110
294	Adenovirus-based genetic vaccines for biodefense. *Human Gene Therapy*, **2005**, 16, 157-68	4.8	49
293	Diet-dependent cardiovascular lipid metabolism controlled by hepatic LXRalpha. *Cell Metabolism*, **2005**, 1, 297-308	24.6	44
292	Innate immune responses to adenoviral vector-mediated acute pancreatitis. *Pancreas*, **2005**, 30, 122-9	2.6	20
291	Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. *Blood*, **2005**, 105, 1424-30	2.2	225
290	Utility of PEGylated recombinant adeno-associated viruses for gene transfer. *Journal of Controlled Release*, **2005**, 108, 161-77	11.7	59
289	Use of chimeric adenoviral vectors to assess capsid neutralization determinants. *Virology*, **2005**, 333, 207-14	3.6	34
288	Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein. *Virology*, **2005**, 335, 34-45	3.6	66

287	Transduction of satellite cells after prenatal intramuscular administration of lentiviral vectors. *Journal of Gene Medicine*, **2005**, 7, 50-8	3.5	37
286	Gene transfer into skeletal muscle using novel AAV serotypes. *Journal of Gene Medicine*, **2005**, 7, 442-51	3.5	94
285	An optimized protocol for detection of E. coli beta-galactosidase in lung tissue following gene transfer. *Histochemistry and Cell Biology*, **2005**, 124, 77-85	2.4	37
284	Human airway epithelial cells sense Pseudomonas aeruginosa infection via recognition of flagellin by Toll-like receptor 5. *Infection and Immunity*, **2005**, 73, 7151-60	3.7	158
283	New recombinant serotypes of AAV vectors. *Current Gene Therapy*, **2005**, 5, 285-97	4.3	410
282	Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice. *Gene Therapy*, **2005**, 12, 427-36	4	91
281	Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 560-5	9.4	68
280	Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. *Blood*, **2005**, 105, 3079-86	2.2	151
279	Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. *Infection and Immunity*, **2005**, 73, 6885-91	3.7	47
278	Creatine kinase, a magnetic resonance-detectable marker gene for quantification of liver-directed gene transfer. *Human Gene Therapy*, **2005**, 16, 1429-38	4.8	24
277	Widespread dispersion of adeno-associated virus serotype 1 and adeno-associated virus serotype 6 vectors in the rat central nervous system and in human glioblastoma multiforme xenografts. *Human Gene Therapy*, **2005**, 16, 381-92	4.8	25
276	No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. *Molecular Therapy*, **2005**, 12, 299-306	11.7	84
275	Proteasome inhibition enhances AAV-mediated transgene expression in human synoviocytes in vitro and in vivo. *Molecular Therapy*, **2005**, 11, 600-7	11.7	49
274	Targeting viral-mediated transduction to the lung airway epithelium with the anti-inflammatory cationic lipid dexamethasone-spermine. *Molecular Therapy*, **2005**, 12, 502-9	11.7	21
273	Pharmacologically regulated regeneration of functional human pancreatic islets. *Molecular Therapy*, **2005**, 11, 105-11	11.7	14
272	Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. *Clinical Cancer Research*, **2005**, 11, 7444-53	12.9	112
271	Nonhuman primate models for diabetic ocular neovascularization using AAV2-mediated overexpression of vascular endothelial growth factor. *Diabetes*, **2005**, 54, 1141-9	0.9	52
270	Creatine Kinase, a Magnetic Resonance-Detectable Marker Gene for Quantification of Liver-Directed Gene Transfer. *Human Gene Therapy*, **2005**, 051101065026001	4.8	

269	SARS vaccine: progress and challenge. *Cellular and Molecular Immunology*, **2005**, 2, 101-5	15.4	10
268	558. Anti-SARS Humoral and Cellular Immunity Evoked by an Adenovirus Vector Expressing Spike Glycoprotein from SARS Coronavirus. *Molecular Therapy*, **2004**, 9, S210	11.7	2
267	368. Pseudotyping HIV Vector with the Spike Envelope Protein of SARS-CoV for Studying Viral Tropism, Immunology and Gene Therapy Applications. *Molecular Therapy*, **2004**, 9, S140	11.7	78
266	Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. *Human Gene Therapy*, **2004**, 15, 519-30	4.8	81
265	PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. *Journal of Virology*, **2004**, 78, 912-21	6.6	123
264	Macaque model for severe acute respiratory syndrome. *Journal of Virology*, **2004**, 78, 11401-4	6.6	114
263	Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. *Journal of Virology*, **2004**, 78, 11416-21	6.6	116
262	Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. *Clinical Cancer Research*, **2004**, 10, 1535-44	12.9	26
261	Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. *Journal of Virology*, **2004**, 78, 7392-9	6.6	86
260	Generation of a mouse expressing a conditional knockout of the hepatocyte growth factor gene: demonstration of impaired liver regeneration. *DNA and Cell Biology*, **2004**, 23, 592-603	3.6	31
259	Adeno-associated virus and lentivirus pseudotypes for lung-directed gene therapy. *Proceedings of the American Thoracic Society*, **2004**, 1, 309-14		14
258	Clades of Adeno-associated viruses are widely disseminated in human tissues. *Journal of Virology*, **2004**, 78, 6381-8	6.6	749
257	AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice. *Molecular Therapy*, **2004**, 9, 231-40	11.7	111
256	Complete nucleotide sequences and genome organization of four chimpanzee adenoviruses. *Virology*, **2004**, 324, 361-72	3.6	44
255	Perceived quality of life in schizophrenia: relationships to sleep quality. *Quality of Life Research*, **2004**, 13, 783-91	3.7	103
254	Novel adenoviral vectors coding for GFP-tagged wtCFTR and deltaF508-CFTR: characterization of expression and electrophysiological properties in A549 cells. *Pflugers Archiv European Journal of Physiology*, **2004**, 449, 278-87	4.6	8
253	Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. *Journal of Gene Medicine*, **2004**, 6, 663-72	3.5	85
252	MR and fluorescent imaging of low-density lipoprotein receptors. *Academic Radiology*, **2004**, 11, 1251-9	4.3	69

251	Transduction of human islets with pseudotyped lentiviral vectors. *Human Gene Therapy*, **2004**, 15, 211-9	4.8	37
250	Induction of CD8+ T cells to an HIV-1 antigen upon oral immunization of mice with a simian E1-deleted adenoviral vector. *Vaccine*, **2004**, 22, 697-703	4.1	29
249	Recombinant adeno-associated virus preferentially transduces human, compared to mouse, synovium: implications for arthritis therapy. *Modern Rheumatology*, **2004**, 14, 18-24	3.3	8
248	Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. *Blood*, **2004**, 103, 1253-60	10.2	168
247	Autoimmune anemia in macaques following erythropoietin gene therapy. *Blood*, **2004**, 103, 3303-4	2.2	107
246	Erythropoietin gene therapy leads to autoimmune anemia in macaques. *Blood*, **2004**, 103, 3300-2	2.2	123
245	1048. Long-Term Regulated Gene Expression in Non-Human Primates Using a Single Non-Recombinogenic AAV Vector. *Molecular Therapy*, **2004**, 9, S402	11.7	2
244	Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung. *Molecular Therapy*, **2003**, 8, 777-89	11.7	93
243	Regulated expression of erythropoietin from an AAV vector safely improves the anemia of beta-thalassemia in a mouse model. *Molecular Therapy*, **2003**, 7, 493-7	11.7	46
242	In vivo quantitative noninvasive imaging of gene transfer by single-photon emission computerized tomography. *Human Gene Therapy*, **2003**, 14, 255-61	4.8	30
241	Airway epithelia regulate expression of human beta-defensin 2 through Toll-like receptor 2. *FASEB Journal*, **2003**, 17, 1727-9	0.9	86
240	Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. *Journal of Immunology*, **2003**, 171, 6774-9	5.3	103
239	Mucosally delivered E1-deleted adenoviral vaccine carriers induce transgene product-specific antibody responses in neonatal mice. *Journal of Immunology*, **2003**, 171, 4287-93	5.3	31
238	A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. *Journal of Immunology*, **2003**, 170, 1416-22	5.3	187
237	Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung. *Molecular Therapy*, **2003**, 8, 777	11.7	
236	Physiological modulation of CFTR activity by AMP-activated protein kinase in polarized T84 cells. *American Journal of Physiology - Cell Physiology*, **2003**, 284, C1297-308	5.4	95
235	T helper cell-independent antibody responses to the transgene product of an e1-deleted adenoviral vaccine require NK1.1 T cells. *Virology*, **2003**, 305, 397-405	3.6	3
234	Cathelicidins--a family of multifunctional antimicrobial peptides. *Cellular and Molecular Life Sciences*, **2003**, 60, 711-20	10.3	321

233	Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID mice. *Journal of Investigative Dermatology*, **2003**, 120, 683-92	4.3	43
232	High throughput creation of recombinant adenovirus vectors by direct cloning, green-white selection and I-Sce I-mediated rescue of circular adenovirus plasmids in 293 cells. *Gene Therapy*, **2003**, 10, 1926-30	4	32
231	Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. *Molecular Genetics and Metabolism*, **2003**, 80, 148-58	3.7	1115
230	Human fetal trachea-SCID mouse xenografts: efficacy of vesicular stomatitis virus-G pseudotyped lentiviral-mediated gene transfer. *Journal of Pediatric Surgery*, **2003**, 38, 834-9	2.6	27
229	Correction of the dystrophic phenotype by in vivo targeting of muscle progenitor cells. *Human Gene Therapy*, **2003**, 14, 1441-9	4.8	49
228	Efficient trans-splicing in the retina expands the utility of adeno-associated virus as a vector for gene therapy. *Human Gene Therapy*, **2003**, 14, 37-44	4.8	74
227	Efficient transduction of human monocyte-derived dendritic cells by chimpanzee-derived adenoviral vector. *Human Gene Therapy*, **2003**, 14, 533-44	4.8	25
226	Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. *Journal of Virology*, **2003**, 77, 10780-9	6.6	119
225	Delivery of adeno-associated virus vectors to the fetal retina: impact of viral capsid proteins on retinal neuronal progenitor transduction. *Journal of Virology*, **2003**, 77, 7957-63	6.6	39
224	Adeno-associated viruses undergo substantial evolution in primates during natural infections. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 6081-6	11.5	260
223	In vivo somatic cell gene transfer of an engineered Noggin mutein prevents BMP4-induced heterotopic ossification. *Journal of Bone and Joint Surgery - Series A*, **2003**, 85, 2332-42	5.6	114
222	Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost. *Journal of General Virology*, **2003**, 84, 203-213	4.9	26
221	Constitutive and regulated expression of processed insulin following in vivo hepatic gene transfer. *Gene Therapy*, **2002**, 9, 963-71	4	71
220	Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. *Nature Medicine*, **2002**, 8, 864-71	50.5	311
219	A new scalable method for the purification of recombinant adenovirus vectors. *Human Gene Therapy*, **2002**, 13, 1921-34	4.8	55
218	beta-Defensin 1 contributes to pulmonary innate immunity in mice. *Infection and Immunity*, **2002**, 70, 3068-72	3.7	207
217	A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. *Human Gene Therapy*, **2002**, 13, 163-75	4.8	300
216	Rep/Cap gene amplification and high-yield production of AAV in an A549 cell line expressing Rep/Cap. *Molecular Therapy*, **2002**, 5, 644-9	11.7	63

215	Toll-like receptor 4 mediates innate immune responses to Haemophilus influenzae infection in mouse lung. *Journal of Immunology*, **2002**, 168, 810-5	5.3	173
214	Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity. *Journal of Virology*, **2002**, 76, 5711-9	6.6	72
213	Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 11854-9	11.5	1221
212	Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. *Journal of Virology*, **2002**, 76, 2667-75	6.6	170
211	Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. *Journal of Experimental Medicine*, **2002**, 195, 617-24	16.6	278
210	Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. *Molecular Therapy*, **2002**, 6, 490-4	11.7	136
209	Effect of blood collection technique in mice on clinical pathology parameters. *Human Gene Therapy*, **2002**, 13, 155-61	4.8	112
208	PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. *Human Gene Therapy*, **2002**, 13, 1887-900	4.8	146
207	Efficient transduction of liver and muscle after in utero injection of lentiviral vectors with different pseudotypes. *Molecular Therapy*, **2002**, 6, 349-58	11.7	84
206	Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. *Molecular Therapy*, **2002**, 5, 528-37	11.7	181
205	Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye. *Molecular Therapy*, **2002**, 6, 238-42	11.7	84
204	Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. *Journal of Clinical Investigation*, **2002**, 110, 499-504	15.9	97
203	Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. *Journal of Clinical Investigation*, **2002**, 110, 499-504	15.9	54
202	Adenoviruses as Vectors for Human Gene Therapy **2002**, 31-49		
201	Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. *Journal of General Virology*, **2002**, 83, 151-155	4.9	48
200	Construction of adenoviral vectors. *Molecular Biotechnology*, **2001**, 18, 63-70	3	20
199	Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. *Nature Biotechnology*, **2001**, 19, 225-30	44.5	260
198	Pharmacologically regulated gene expression in the retina following transduction with viral vectors. *Gene Therapy*, **2001**, 8, 442-6	4	30

197	Development of formulations that enhance physical stability of viral vectors for gene therapy. *Gene Therapy*, **2001**, 8, 1281-90	4	121
196	Regulated gene expression in gene therapy. *Annals of the New York Academy of Sciences*, **2001**, 953, 53-63	6.5	17
195	Adenovirus-mediated gene transfer to liver. *Advanced Drug Delivery Reviews*, **2001**, 46, 205-9	18.5	34
194	"Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. *Journal of Virology*, **2001**, 75, 4792-801	6.6	206
193	Biology of E1-deleted adenovirus vectors in nonhuman primate muscle. *Journal of Virology*, **2001**, 75, 5222-9	6.6	30
192	Differences in the human and mouse amino-terminal leader peptides of ornithine transcarbamylase affect mitochondrial import and efficacy of adenoviral vectors. *Human Gene Therapy*, **2001**, 12, 1035-46	4.8	10
191	Selective repopulation of normal mouse liver by hepatocytes transduced in vivo with recombinant adeno-associated virus. *Human Gene Therapy*, **2001**, 12, 45-50	4.8	22
190	Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. *Molecular Therapy*, **2001**, 3, 28-35	11.7	282
189	A single-step affinity column for purification of serotype-5 based adeno-associated viral vectors. *Molecular Therapy*, **2001**, 4, 372-4	11.7	77
188	In vivo detection of gene expression in liver by 31P nuclear magnetic resonance spectroscopy employing creatine kinase as a marker gene. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 5205-10	11.5	49
187	Replication-defective vector based on a chimpanzee adenovirus. *Journal of Virology*, **2001**, 75, 11603-13	6.6	225
186	Development of novel formulations that enhance adenoviral-mediated gene expression in the lung in vitro and in vivo. *Molecular Therapy*, **2001**, 4, 22-8	11.7	41
185	Rhesus monkey (Macaca mulatta) mucosal antimicrobial peptides are close homologues of human molecules. *Vaccine Journal*, **2001**, 8, 370-5		33
184	Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. *Journal of Virology*, **2001**, 75, 6199-203	6.6	186
183	Salt-independent abnormality of antimicrobial activity in cystic fibrosis airway surface fluid. *American Journal of Respiratory Cell and Molecular Biology*, **2001**, 25, 21-5	5.7	68
182	Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. *Human Molecular Genetics*, **2001**, 10, 3075-81	5.6	287
181	Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. *Molecular Therapy*, **2001**, 3, 697-707	11.7	344
180	Intra-arterial delivery of a recombinant adenovirus does not increase gene transfer to tumor cells in a rat model of metastatic colorectal carcinoma. *Molecular Therapy*, **2001**, 4, 29-35	11.7	14

179	Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. *Human Gene Therapy*, **2001**, 12, 205-15	4.8	123
178	Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. *Molecular Therapy*, **2001**, 3, 708-22	11.7	304
177	Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. *Human Gene Therapy*, **2001**, 12, 71-6	4.8	254
176	iNOS Expression In Dystrophinopathies Can Be Reduced By Somatic Gene Transfer of Dystrophin or Utrophin. *Molecular Medicine*, **2001**, 7, 355-364	6.2	22
175	Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. *Journal of Clinical Investigation*, **2001**, 108, 83-95	15.9	15
174	Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. *Journal of Clinical Investigation*, **2001**, 108, 83-95	15.9	31
173	Production of recombinant adeno-associated virus. *Advances in Virus Research*, **2000**, 55, 529-43	10.7	14
172	Genotype spectrum of ornithine transcarbamylase deficiency: correlation with the clinical and biochemical phenotype. *American Journal of Medical Genetics Part A*, **2000**, 93, 313-9		93
171	The ethical challenges of in utero gene therapy. *Nature Genetics*, **2000**, 24, 107	36.3	12
170	A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. *Cancer Gene Therapy*, **2000**, 7, 1511-8	5.4	45
169	Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mouse. *Gene Therapy*, **2000**, 7, 1761-7	4	31
168	Electron Microscopic Evaluation of Vector Quality for Gene Therapy. *Microscopy and Microanalysis*, **2000**, 6, 858-859	0.5	
167	Intravenous Injection of an Adenovirus Encoding Hepatocyte Growth Factor Results in Liver Growth and Has a Protective Effect Against Apoptosis. *Molecular Medicine*, **2000**, 6, 96-103	6.2	38
166	CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells. *Journal of Virology*, **2000**, 74, 8003-10	6.6	98
165	Th2-dependent B cell responses in the absence of CD40-CD40 ligand interactions. *Journal of Immunology*, **2000**, 164, 248-55	5.3	17
164	Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer. *Molecular Therapy*, **2000**, 1, 119-29	11.7	83
163	A quantitative nonimmunogenic transgene product for evaluating vectors in nonhuman primates. *Molecular Therapy*, **2000**, 2, 657-9	11.7	7
162	Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors. *Molecular Therapy*, **2000**, 1, 323-9	11.7	98

161	Adeno-associated virus mediates long-term gene transfer and delivery of chondroprotective IL-4 to murine synovium. *Molecular Therapy*, **2000**, 2, 147-52	11.7	86
160	A cell line for high-yield production of E1-deleted adenovirus vectors without the emergence of replication-competent virus. *Human Gene Therapy*, **2000**, 11, 213-9	4.8	31
159	In vivo selection of hepatocytes transduced with adeno-associated viral vectors. *Molecular Therapy*, **2000**, 1, 414-22	11.7	32
158	Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. *Human Gene Therapy*, **2000**, 11, 2079-91	4.8	152
157	Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions. *Journal of Virology*, **2000**, 74, 3345-52	6.6	52
156	Bacterial phosphorylcholine decreases susceptibility to the antimicrobial peptide LL-37/hCAP18 expressed in the upper respiratory tract. *Infection and Immunity*, **2000**, 68, 1664-71	3.7	153
155	Combination therapy with lamivudine and adenovirus causes transient suppression of chronic woodchuck hepatitis virus infections. *Journal of Virology*, **2000**, 74, 11754-63	6.6	30
154	Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. *Journal of Virology*, **2000**, 74, 2420-5	6.6	159
153	Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. *Human Gene Therapy*, **2000**, 11, 1713-22	4.8	123
152	Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor. *Molecular Therapy*, **2000**, 2, 256-61	11.7	56
151	Efficient Mitochondrial Import of Newly Synthesized Ornithine Transcarbamylase (OTC) and Correction of Secondary Metabolic Alterations in spfash Mice following Gene Therapy of OTC Deficiency. *Molecular Medicine*, **1999**, 5, 244-253	6.2	9
150	Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. *Infection and Immunity*, **1999**, 67, 6084-9	3.7	247
149	Adenoviral RB2/p130 gene transfer inhibits smooth muscle cell proliferation and prevents restenosis after angioplasty. *Circulation Research*, **1999**, 85, 1032-9	15.7	59
148	bcl-2 gene therapy exacerbates excitotoxicity. *Human Gene Therapy*, **1999**, 10, 1715-20	4.8	18
147	Recombinant adenovirus gene transfer in adults with partial ornithine transcarbamylase deficiency (OTCD). *Human Gene Therapy*, **1999**, 10, 2419-37	4.8	40
146	Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. *Human Gene Therapy*, **1999**, 10, 463-75	4.8	31
145	Fas-Fas ligand interactions play a major role in effector functions of cytotoxic T lymphocytes after adenovirus vector-mediated gene transfer. *Human Gene Therapy*, **1999**, 10, 259-69	4.8	32
144	A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. *Human Gene Therapy*, **1999**, 10, 2973-85	4.8	122

143	Adenoviral vector-mediated gene therapy in the mouse lung: no role of Fas-Fas ligand interactions for elimination of transgene expression in bronchioepithelial cells. *Human Gene Therapy*, **1999**, 10, 2839-46	4.8	8
142	Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 8657-62	11.5	162
141	Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 9920-5	11.5	211
140	Constitutive and Regulated Expression in the Systemic Delivery of Erythropoietin Following Skeletal Muscle Transduction with DNA Viral Vectors. *Nature Biotechnology*, **1999**, 17, 13-13	44.5	
139	Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. *Nature Medicine*, **1999**, 5, 439-43	50.5	185
138	Immune responses to adenovirus and adeno-associated virus in humans. *Gene Therapy*, **1999**, 6, 1574-83	4	593
137	Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. *Science*, **1999**, 283, 88-91	33.3	290
136	Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. *Human Gene Therapy*, **1999**, 10, 2515-26	4.8	107
135	Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV. *Vision Research*, **1999**, 39, 2545-53	2.1	137
134	BAPS Prize--1997. Fetal gene therapy: efficacy, toxicity, and immunologic effects of early gestation recombinant adenovirus. British Association of Paediatric Surgeons. *Journal of Pediatric Surgery*, **1999**, 34, 235-41	2.6	38
133	Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice. *Experimental Neurology*, **1999**, 160, 17-27	5.7	117
132	Mouse beta-defensin 3 is an inducible antimicrobial peptide expressed in the epithelia of multiple organs. *Infection and Immunity*, **1999**, 67, 3542-7	3.7	148
131	Overexpression of cyclin A inhibits augmentation of recombinant adeno-associated virus transduction by the adenovirus E4orf6 protein. *Journal of Virology*, **1999**, 73, 10010-9	6.6	21
130	Gene therapy vectors based on adeno-associated virus type 1. *Journal of Virology*, **1999**, 73, 3994-4003	6.6	425
129	Transduction of well-differentiated airway epithelium by recombinant adeno-associated virus is limited by vector entry. *Journal of Virology*, **1999**, 73, 6085-8	6.6	58
128	The innate immune system in cystic fibrosis lung disease. *Journal of Clinical Investigation*, **1999**, 103, 303-7	15.9	151
127	Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. *Journal of Clinical Investigation*, **1999**, 103, 1113-7	15.9	141
126	Correction of ureagenesis after gene transfer in an animal model and after liver transplantation in humans with ornithine transcarbamylase deficiency. *Pediatric Research*, **1999**, 46, 588-93	3.2	14

125	In vivo measurement of ureagenesis with stable isotopes. *Journal of Inherited Metabolic Disease*, **1998**, 21 Suppl 1, 21-9	5.4	18
124	Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency. *Journal of Inherited Metabolic Disease*, **1998**, 21 Suppl 1, 119-37	5.4	31
123	Fas ligand--a double-edged sword. *Nature Biotechnology*, **1998**, 16, 1011-2	44.5	115
122	Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. *Gene Therapy*, **1998**, 5, 309-19	4	119
121	High throughput method for creating and screening recombinant adenoviruses. *Gene Therapy*, **1998** , 5, 1148-52	4	44
120	Efficient induction of protective anti-malaria immunity by recombinant adenovirus. *Vaccine*, **1998**, 16, 1812-7	4.1	34
119	Methods of gene delivery. *Hematology/Oncology Clinics of North America*, **1998**, 12, 483-501	3.1	61
118	High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. *Human Gene Therapy*, **1998**, 9, 2353-62	4.8	169
117	Selective gene transfer into the liver of non-human primates with E1-deleted, E2A-defective, or E1-E4 deleted recombinant adenoviruses. *Human Gene Therapy*, **1998**, 9, 671-9	4.8	42
116	Evaluating the potential of germ line transmission after intravenous administration of recombinant adenovirus in the C3H mouse. *Human Gene Therapy*, **1998**, 9, 2135-42	4.8	58
115	Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. *Human Gene Therapy*, **1998**, 9, 2121-33	4.8	185
114	Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. *Human Gene Therapy*, **1998**, 9, 1083-92	4.8	301
113	Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 14411-6	11.5	110
112	The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 9541-6	11.5	590
111	Mouse beta-defensin 1 is a salt-sensitive antimicrobial peptide present in epithelia of the lung and urogenital tract. *Infection and Immunity*, **1998**, 66, 1225-32	3.7	148
110	Adeno-associated virus as a vector for liver-directed gene therapy. *Journal of Virology*, **1998**, 72, 10222-6	6.6	137
109	Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. *Journal of Virology*, **1998**, 72, 2945-54	6.6	104
108	Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. *Journal of Virology*, **1998**, 72, 4212-23	6.6	355

107	Role of E4 in eliciting CD4 T-cell and B-cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs. *Journal of Virology*, **1998**, 72, 6138-45	6.6	64
106	Lentiviral vectors for gene therapy of cystic fibrosis. *Human Gene Therapy*, **1997**, 8, 2261-8	4.8	102
105	Adenovirus-mediated gene transfer by perivitelline microinjection of mouse, rat, and cow embryos. *Biology of Reproduction*, **1997**, 56, 119-24	3.9	18
104	Intracranial administration of adenovirus expressing HSV-TK in combination with ganciclovir produces a dose-dependent, self-limiting inflammatory response. *Human Gene Therapy*, **1997**, 8, 943-54	4.8	56
103	The transmembrane domain of diphtheria toxin improves molecular conjugate gene transfer. *Biochemical Journal*, **1997**, 321 (Pt 1), 49-58	3.8	51
102	Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 5804-9	11.5	431
101	Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. *Cell*, **1997**, 88, 553-60	56.2	936
100	Making space for intestinal gene therapy. *Gastroenterology*, **1997**, 112, 1753-6	13.3	4
99	Recombinant adeno-associated virus for muscle directed gene therapy. *Nature Medicine*, **1997**, 3, 306-12	50.5	594
98	Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. *Journal of Clinical Investigation*, **1997**, 100, 1951-7	15.9	157
97	Adenovirus-mediated in vivo gene transfer rapidly protects ornithine transcarbamylase-deficient mice from an ammonium challenge. *Pediatric Research*, **1997**, 41, 527-34	3.2	27
96	Gene transfer by adenovirus in smooth muscle cells. *Respiration Physiology*, **1996**, 105, 155-62		2
95	Adenoviruses as gene-delivery vehicles. *New England Journal of Medicine*, **1996**, 334, 1185-7	59.2	406
94	A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. *Human Gene Therapy*, **1996**, 7, 2079-87	4.8	86
93	CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. *Science*, **1996**, 273, 1862-4	33.3	358
92	Safety of intrapleurally administered recombinant adenovirus carrying herpes simplex thymidine kinase DNA followed by ganciclovir therapy in nonhuman primates. *Human Gene Therapy*, **1996**, 7, 2225-33	4.8	38
91	Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. *Human Gene Therapy*, **1996**, 7, 1465-82	4.8	101
90	Targeted retroviral gene transfer into the rat biliary tract. *Somatic Cell and Molecular Genetics*, **1996** , 22, 21-9		7

89	Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. *Virology*, **1996**, 217, 11-22	3.6	251
88	A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. *Virology*, **1996**, 219, 220-7	3.6	218
87	Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. *Nature Genetics*, **1996**, 13, 54-62	36.3	152
86	A pharmacologic rheostat for gene therapy. *Nature Medicine*, **1996**, 2, 977-8	50.5	5
85	Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors. *Journal of Biological Chemistry*, **1996**, 271, 3639-46	5.4	130
84	Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. *Human Molecular Genetics*, **1996**, 5, 1703-12	5.6	119
83	Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. *Human Gene Therapy*, **1996**, 7, 1555-66	4.8	149
82	In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. *Human Gene Therapy*, **1996**, 7, 1907-14	4.8	137
81	Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: a phase 1 trial (BB-IND 6274). *Human Gene Therapy*, **1996**, 7, 2047-57	4.8	27
80	Hepatic expression of the catalytic subunit of the apolipoprotein B mRNA editing enzyme (apobec-1) ameliorates hypercholesterolemia in LDL receptor-deficient rabbits. *Human Gene Therapy*, **1996**, 7, 943-57	4.8	59
79	Animal models of human disease for gene therapy. *Journal of Clinical Investigation*, **1996**, 97, 1138-41	15.9	12
78	Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia. *Annals of Surgery*, **1996**, 223, 116-26	7.8	82
77	Gene therapy in a xenograft model of cystic fibrosis lung corrects chloride transport more effectively than the sodium defect. *Nature Genetics*, **1995**, 9, 126-31	36.3	79
76	Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. *Nature Medicine*, **1995**, 1, 890-3	50.5	229
75	A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. *Nature Medicine*, **1995**, 1, 1148-54	50.5	440
74	Characterization of stem cells in human airway capable of reconstituting a fully differentiated bronchial epithelium. *Somatic Cell and Molecular Genetics*, **1995**, 21, 61-73		24
73	Adenovirus-mediated gene transfer to liver. *Advanced Drug Delivery Reviews*, **1995**, 17, 303-307	18.5	8
72	Gene therapy of hypercholesterolemic disorders. *Trends in Cardiovascular Medicine*, **1995**, 5, 205-9	6.9	4

71	Prospects for gene therapy in ornithine carbamoyltransferase deficiency and other urea cycle disorders. *Mental Retardation and Developmental Disabilities Research Reviews*, **1995**, 1, 62-70		4
70	The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. *Journal of Clinical Investigation*, **1995**, 95, 1403-8	15.9	157
69	A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. *New England Journal of Medicine*, **1995**, 333, 823-31	59.2	520
68	Transfer of the CFTR gene to the lung of nonhuman primates with E1-deleted, E2a-defective recombinant adenoviruses: a preclinical toxicology study. *Human Gene Therapy*, **1995**, 6, 839-51	4.8	82
67	Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. *Annals of Surgery*, **1995**, 222, 78-86	7.8	86
66	Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 7257-61	11.5	232
65	Expression of alpha v beta 5 integrin is necessary for efficient adenovirus-mediated gene transfer in the human airway. *Journal of Virology*, **1995**, 69, 5951-8	6.6	142
64	Gene therapy for cystic fibrosis: challenges and future directions. *Journal of Clinical Investigation*, **1995**, 96, 2547-54	15.9	62
63	Gene therapy of cystic fibrosis lung disease using E1 deleted adenoviruses: a phase I trial. *Human Gene Therapy*, **1994**, 5, 501-19	4.8	78
62	Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. *Human Gene Therapy*, **1994**, 5, 1217-29	4.8	202
61	Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cavity. The University of North Carolina at Chapel Hill. *Human Gene Therapy*, **1994**, 5, 615-39	4.8	99
60	Cystic Fibrosis: Strategies for Gene Therapy. *Seminars in Respiratory and Critical Care Medicine*, **1994** , 15, 439-445	3.9	6
59	Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. *Nature Genetics*, **1994**, 6, 335-41	36.3	515
58	Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. *Nature Genetics*, **1994**, 7, 362-9	36.3	444
57	Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. *Nature*, **1994**, 371, 802-6	50.4	342
56	Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. *Annals of Thoracic Surgery*, **1994**, 57, 1395-401	2.7	114
55	MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. *Immunity*, **1994**, 1, 433-42	32.3	576
54	Biochemical and functional analysis of an adenovirus-based ligand complex for gene transfer. *Biochemical Journal*, **1994**, 299 (Pt 1), 49-58	3.8	43

53	Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **1994**, 91, 4407-11	11.5	1418
52	Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. *Proceedings of the National Academy of Sciences of the United States of America*, **1994**, 91, 6196-200	11.5	551
51	Expression of the cystic fibrosis gene in adult human lung. *Journal of Clinical Investigation*, **1994**, 93, 737-49	15.9	177
50	Molecular basis of defective anion transport in L cells expressing recombinant forms of CFTR. *Human Molecular Genetics*, **1993**, 2, 1253-61	5.6	76
49	Retroviruses: delivery vehicle to the liver. *Current Opinion in Genetics and Development*, **1993**, 3, 110-4	4.9	21
48	Gene therapy: adenovirus vectors. *Current Opinion in Genetics and Development*, **1993**, 3, 499-503	4.9	377
47	Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: toxicity study. *Human Gene Therapy*, **1993**, 4, 771-80	4.8	311
46	An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer. *Proceedings of the National Academy of Sciences of the United States of America*, **1993**, 90, 4601-5	11.5	127
45	Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: biological efficacy study. *Human Gene Therapy*, **1993**, 4, 759-69	4.8	200
44	Expression of an abundant alternatively spliced form of the cystic fibrosis transmembrane conductance regulator (CFTR) gene is not associated with a cAMP-activated chloride conductance. *Human Molecular Genetics*, **1993**, 2, 225-30	5.6	88
43	The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. *Proceedings of the National Academy of Sciences of the United States of America*, **1993**, 90, 9480-4	11.5	303
42	Cell transplantation in liver-directed gene therapy. *Cell Transplantation*, **1993**, 2, 381-400; discussion 407-10	4	40
41	A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. *Nature Genetics*, **1993**, 3, 219-23	36.3	559
40	Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. *Nature Genetics*, **1993**, 4, 27-34	36.3	287
39	Adenovirus-mediated correction of the genetic defect in hepatocytes from patients with familial hypercholesterolemia. *Somatic Cell and Molecular Genetics*, **1993**, 19, 449-58		77
38	Therapeutic strategies for familial hypercholesterolemia based on somatic gene transfer. *American Journal of Cardiology*, **1993**, 72, 59D-63D	3	6
37	Adenoviral-mediated gene transfer to rabbit synovium in vivo. *Journal of Clinical Investigation*, **1993**, 92, 1085-92	15.9	150
36	Hepatocyte transplantation: development of new systems for liver repopulation and gene therapy. *Seminars in Liver Disease*, **1992**, 12, 321-31	7.3	19

35	Ex vivo gene therapy of familial hypercholesterolemia. *Human Gene Therapy*, **1992**, 3, 179-222	4.8	87
34	Transplantation of genetically modified autologous hepatocytes into nonhuman primates: feasibility and short-term toxicity. *Human Gene Therapy*, **1992**, 3, 501-10	4.8	83
33	Role of CFTR in lysosome acidification. *Biochemical and Biophysical Research Communications*, **1992**, 184, 300-5	3.4	21
32	Human cystic fibrosis transmembrane conductance regulator directed to respiratory epithelial cells of transgenic mice. *Nature Genetics*, **1992**, 2, 13-20	36.3	81
31	Submucosal glands are the predominant site of CFTR expression in the human bronchus. *Nature Genetics*, **1992**, 2, 240-8	36.3	590
30	Targeted delivery of antisense oligonucleotides by molecular conjugates. *Somatic Cell and Molecular Genetics*, **1992**, 18, 559-69		45
29	Provocative gene therapy strategy for the treatment of hepatocellular carcinoma. *Hepatology*, **1992**, 16, 273-4	11.2	7
28	In vivo retroviral gene transfer into human bronchial epithelia of xenografts. *Journal of Clinical Investigation*, **1992**, 90, 2598-607	15.9	65
27	Expression of human factor IX in rat capillary endothelial cells: toward somatic gene therapy for hemophilia B. *Proceedings of the National Academy of Sciences of the United States of America*, **1991**, 88, 8101-5	11.5	113
26	Towards liver-directed gene therapy: retrovirus-mediated gene transfer into human hepatocytes. *Somatic Cell and Molecular Genetics*, **1991**, 17, 601-7		26
25	Expression of retroviral transduced human CD18 in murine cells: an in vitro model of gene therapy for leukocyte adhesion deficiency. *Human Gene Therapy*, **1991**, 2, 221-8	4.8	16
24	Expression of human adenosine deaminase in mice reconstituted with retrovirus-transduced hematopoietic stem cells. *Proceedings of the National Academy of Sciences of the United States of America*, **1990**, 87, 439-43	11.5	84
23	Temporary amelioration of hyperlipidemia in low density lipoprotein receptor-deficient rabbits transplanted with genetically modified hepatocytes. *Proceedings of the National Academy of Sciences of the United States of America*, **1990**, 87, 8437-41	11.5	106
22	Correction of CD18-deficient lymphocytes by retrovirus-mediated gene transfer. *Science*, **1990**, 248, 1413-6	33.6	50
21	Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. *Cell*, **1990**, 62, 1227-33	30.2	528
20	Implantation of vascular grafts lined with genetically modified endothelial cells. *Science*, **1989**, 244, 1344-6	33.3	303
19	Retrovirus-mediated transduction of adult hepatocytes. *Proceedings of the National Academy of Sciences of the United States of America*, **1988**, 85, 3014-8	11.5	131
18	Correction of the genetic defect in hepatocytes from the Watanabe heritable hyperlipidemic rabbit. *Proceedings of the National Academy of Sciences of the United States of America*, **1988**, 85, 4421-5	11.5	140

17	Hypoxanthine-guanine phosphoribosyltransferase. Genetic evidence for identical mutations in two partially deficient subjects. *Journal of Clinical Investigation*, **1988**, 82, 2164-7	15.9	22
16	A molecular survey of hypoxanthine-guanine phosphoribosyltransferase deficiency in man. *Journal of Clinical Investigation*, **1986**, 77, 188-95	15.9	91
15	The primary structure and posttranslational modification of human hypoxanthine-guanine phosphoribosyltransferase. *Advances in Experimental Medicine and Biology*, **1984**, 165 Pt B, 39-44	3.6	
14	Genetic mechanism(s) responsible for a deficiency of adenine phosphoribosyltransferase in man. *Advances in Experimental Medicine and Biology*, **1984**, 165 Pt A, 385-9	3.6	1
13	Human adenine phosphoribosyltransferase: characterization from subjects with a deficiency of enzyme activity. *Biochemical Genetics*, **1983**, 21, 1121-34	2.4	7
12	Hypoxanthine-guanine phosphoribosyltransferase deficiency. The molecular basis of the clinical syndromes. *New England Journal of Medicine*, **1983**, 309, 900-10	59.2	119
11	Human hypoxanthine (guanine) phosphoribosyltransferase: an amino acid substitution in a mutant form of the enzyme isolated from a patient with gout. *Proceedings of the National Academy of Sciences of the United States of America*, **1983**, 80, 870-3	11.5	61
10	Molecular basis of hypoxanthine-guanine phosphoribosyltransferase deficiency in a patient with the Lesch-Nyhan syndrome. *Journal of Clinical Investigation*, **1983**, 71, 1331-5	15.9	43
9	Adenosine deaminase deficiency with normal immune function. An acidic enzyme mutation. *Journal of Clinical Investigation*, **1983**, 72, 483-92	15.9	35
8	Human hypoxanthine-guanine phosphoribosyltransferase. Detection of a mutant allele by restriction endonuclease analysis. *Journal of Clinical Investigation*, **1983**, 72, 767-72	15.9	21
7	Human hypoxanthine-guanine phosphoribosyltransferase. Demonstration of structural variants in lymphoblastoid cells derived from patients with a deficiency of the enzyme. *Journal of Clinical Investigation*, **1982**, 69, 706-15	15.9	65
6	Are Health Education Conferences Effective? An Evaluation of Knowledge Gain in a Three-Day Institute. *Health Education*, **1981**, 12, 22-24		4
5	Defective transport and other phenotypes of a periplasmic "leaky" mutant of Escherichia coli K-12. *Journal of Bacteriology*, **1979**, 140, 351-8	3.5	25
4	Purinogenic immunodeficiency diseases. Differential effects of deoxyadenosine and deoxyguanosine on DNA synthesis in human T lymphoblasts. *Journal of Clinical Investigation*, **1979**, 64, 1475-84	15.9	39
3	Molecular mechanism(s) of deoxyribonucleoside toxicity in T-lymphoblasts. *Advances in Experimental Medicine and Biology*, **1979**, 122B, 265-70	3.6	1
2	High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses		1
1	Intranasal gene therapy to prevent infection by SARS-CoV-2 variants		1